WO2002044205A3 - Peptides from ag85 of mycobacterium and uses thereof - Google Patents

Peptides from ag85 of mycobacterium and uses thereof Download PDF

Info

Publication number
WO2002044205A3
WO2002044205A3 PCT/NL2001/000869 NL0100869W WO0244205A3 WO 2002044205 A3 WO2002044205 A3 WO 2002044205A3 NL 0100869 W NL0100869 W NL 0100869W WO 0244205 A3 WO0244205 A3 WO 0244205A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacterium
present
peptides
immunology
vivo
Prior art date
Application number
PCT/NL2001/000869
Other languages
French (fr)
Other versions
WO2002044205A2 (en
Inventor
Thomas Henricus Maria Ottenhof
Annemieke Geluk
Original Assignee
Academisch Ziekenhuis Leiden
Thomas Henricus Maria Ottenhof
Annemieke Geluk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden, Thomas Henricus Maria Ottenhof, Annemieke Geluk filed Critical Academisch Ziekenhuis Leiden
Priority to AU2002222811A priority Critical patent/AU2002222811A1/en
Publication of WO2002044205A2 publication Critical patent/WO2002044205A2/en
Publication of WO2002044205A3 publication Critical patent/WO2002044205A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Abstract

The present invention relates to the field of immunology. In particularly the invention provides a peptide derived from an Ag85 protein of mycobacterium comprising 8-11 amino acid residues, said peptide capable of inducing proliferation of MHC class I-restricted CD8+ T cells in vivo. One example for use of the present invention is a novel vaccine composition against mycobacterium.
PCT/NL2001/000869 2000-11-30 2001-11-30 Peptides from ag85 of mycobacterium and uses thereof WO2002044205A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002222811A AU2002222811A1 (en) 2000-11-30 2001-11-30 Peptides from ag85 of mycobacterium and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00204268.7 2000-11-30
EP00204268A EP1211260A1 (en) 2000-11-30 2000-11-30 Peptides from Ag85 of mycobacterium and uses thereof

Publications (2)

Publication Number Publication Date
WO2002044205A2 WO2002044205A2 (en) 2002-06-06
WO2002044205A3 true WO2002044205A3 (en) 2002-10-17

Family

ID=8172363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2001/000869 WO2002044205A2 (en) 2000-11-30 2001-11-30 Peptides from ag85 of mycobacterium and uses thereof

Country Status (3)

Country Link
EP (1) EP1211260A1 (en)
AU (1) AU2002222811A1 (en)
WO (1) WO2002044205A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101468201B (en) * 2007-12-27 2012-09-05 上海万兴生物制药有限公司 Preparation of Mycobacterium tuberculosis polyvalent recombinant protein vaccine
CN108693345A (en) * 2018-04-12 2018-10-23 北京睿达时代科技有限公司 For the combination serum markers detection reagent of tuberculosis screening and diagnosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419355A1 (en) * 1989-09-19 1991-03-27 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
WO2001058461A1 (en) * 2000-02-10 2001-08-16 Glaxo Group Limited Mycobacterium ag85 complex-specific t cell peptides and use in diagnostic and therapeutic applications thereof
WO2001070991A1 (en) * 2000-03-20 2001-09-27 Glaxo Group Limited Vaccine against mycobacterium infection based on epitopes of ag85 complex

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419355A1 (en) * 1989-09-19 1991-03-27 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
WO2001058461A1 (en) * 2000-02-10 2001-08-16 Glaxo Group Limited Mycobacterium ag85 complex-specific t cell peptides and use in diagnostic and therapeutic applications thereof
WO2001070991A1 (en) * 2000-03-20 2001-09-27 Glaxo Group Limited Vaccine against mycobacterium infection based on epitopes of ag85 complex

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENIS O ET AL: "Vaccination with plasmid DNA encoding Mycobacterial Antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 66, no. 4, April 1998 (1998-04-01), pages 1527 - 1533, XP002173898, ISSN: 0019-9567 *
GELUK A ET AL: "Identification of major epitopes of M. tuberculosis Ag85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.", IMMUNOBIOLOGY, vol. 203, no. 1-2, 1 December 2000 (2000-12-01), Joint Annual Meeting of the German and Dutch Societies of Immunology;Duseldorf, Germany; November 29-December 02, 2000, pages 317, XP000999159, ISSN: 0171-2985 *
LEE B-Y ET AL: "T-cell epitope mapping of the three most abundant extracellular proteins of Mycobacterium tuberculosis in outbred guinea pigs", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 67, no. 5, May 1999 (1999-05-01), pages 2665 - 2670, XP002168051, ISSN: 0019-9567 *
SMITH S M ET AL: "Role of CD8+ T cells in mycobacterial infections", IMMUNOLOGY AND CELL BIOLOGY, CARLTON, AU, vol. 78, August 2000 (2000-08-01), pages 325 - 333, XP002173901 *

Also Published As

Publication number Publication date
EP1211260A1 (en) 2002-06-05
WO2002044205A2 (en) 2002-06-06
AU2002222811A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
WO2009025117A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same
EP1917970A3 (en) Hla binding peptides and their uses
DK0643726T3 (en) Human p53 protein peptides for use in compositions that induce human T cell response and human p53 protein
BR9708220A (en) Hla-a2.1 binding peptides and their uses
BR9406652A (en) Composition
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
AU2001298049A1 (en) Hla class i and ii binding peptides and their uses
WO2009025116A1 (en) Cdh3 peptide and medicinal agent comprising the same
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
WO2001018035A3 (en) Muc-1 derived peptides
WO2003028758A1 (en) Novel method of inducing antigen-specific t cells
BR9910639A (en) Anti-angiogenic drugs comprising peptide
WO2001079274A3 (en) Tuberculosis antigens and methods of use thereof
WO2005011730A8 (en) Microsome vaccine
WO2005090988A3 (en) Mycobacterium tuberculosis infection diagnostic test
BR0017136A (en) Hla-binding peptides and their uses.
WO2002088328A3 (en) Method for generating highly active human dendritic cells from monocytes
DK1530637T3 (en) Carlsberg subtilisin proteins with reduced immunogenicity
GB9722320D0 (en) Human cell cycle checkpoint proteins
EP2502998A3 (en) Recombinant toxin A/ToxinB vaccine against clostridium difficile
EP1071443A4 (en) Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof
WO2001023560A3 (en) Isolated peptides which bind to mhc class ii molecules, and uses thereof
WO2002044205A3 (en) Peptides from ag85 of mycobacterium and uses thereof
WO1994026903A3 (en) Human influenza virus peptides binding hla-i molecule
EP1829552A3 (en) Chlamydia PMP proteins, gene sequences and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP